NanoViricides
Manufacturing · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Controls Dr, Shelton, Connecticut, 064...Phone Number
(203) 937-6137Website
www.nanoviricides.comRevenue
-Stock Symbol
NNVCIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NanoViricides
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, wRead more
NanoViricides Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NanoViricides your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NanoViricides
Earning: See what the market has to say on NanoViricides recently announced quarterly report
Check if NanoViricides has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NanoViricides has new funding data
Check out if NanoViricides is spiking on competitors!
NanoViricides, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when NanoViricides launches new products
Click to see if NanoViricides had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined NanoViricides as Masked Content
Find 3 more new buyers
Compare Similar Companies to NanoViricides
Compare insights from companies similar to NanoViricides, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NanoViricides is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NanoViricides is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NanoViricides.
NanoViricides financials insights
Gather financial insights about NanoViricides, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$6M
Stock/Share Issuance
$2M
NanoViricides Tech Stack
A closer look at the technologies used by NanoViricides
Most Recent Scoops
Funding
Funding
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
NanoViricides News & Media
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre ... - TradingView
NanoViricides completed a registered direct offering for approximately $2.0 million, issuing common stock and accompanying warrants, and agreed to short-term issuance limits and a resale registration timeline. The company also appointed D. Boral Capital as exclusive placement agent on customary ter…NanoViricides to Participate at D. Boral Capital Global Conference in NYC
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diwan, PhD, will offer one-on-one meetings on the same day from 9:45AM to 2:45PM ET. […]NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financingsNanoViricides Secures $6 Million Through Securities Offering - TipRanks.com
An update from NanoViricides ( ($NNVC) ) is now available. On November 10, 2025, NanoViricides, Inc. entered into a securities purchase agreement with an institutio...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NanoViricides
Sign Up For FreeTo access detailed company insights
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; N... Read More
